title: Follow-up in colorectal cancer patients: a cost-benefit analysis.
abstract: BACKGROUND
  No conclusive evidence exists concerning the effectiveness of follow-up programs after curative surgery for colorectal cancer, and presently cost-benefit analyses have not indicated that follow-up strategies increase survival or quality of life.
  
  
  METHODS
  Five hundred five patients who survived curative surgery for stage I-III colorectal adenocarcinoma were closely followed for at least 4 years.
  
  
  RESULTS
  One hundred forty-one (28%) patients had recurrence. Of these, 32 underwent one or more surgical procedures for cure, whereas 109 could only benefit from palliation. Eighteen were cured. The mean survival of all recurrent cases was 44.4 months. Of those operated on with curative intent, the mean survival was 69.3 months compared with 37.1 months in those operated on with palliative intent. Of those 18 patients who were cured by reoperative surgery, the average survival was 81.4 months. The overall follow-up cost was $1,914,900 (U.S.) for the 505 patients; $13,580 (U.S.) for each recurrence, $59,841 (U.S.) for each case treated for cure, and $136,779 (U.S.) for those effectively cured.
  
  
  CONCLUSIONS
  Careful postoperative monitoring is expensive yet effective when one considers that one-quarter of the detected recurrences were suitable for potentially curative second surgery; however, only 3.6% of the original group were effectively cured. Follow-up programs should be tailored according to the stage and site of the primary to reduce costs.
authors.affiliation: Istituto di Chirurgia d'Urgenza, Università di Milano, Italy.
authors.forename: R A
authors.initials: RA
authors.lastname: Audisio
authors.forename: P
authors.initials: P
authors.lastname: Setti-Carraro
authors.forename: M
authors.initials: M
authors.lastname: Segala
authors.forename: D
authors.initials: D
authors.lastname: Capko
authors.forename: B
authors.initials: B
authors.lastname: Andreoni
authors.forename: G
authors.initials: G
authors.lastname: Tiberio
mesh_terms: D003110:Colonic Neoplasms / Q000191:economics / Q000401:mortality / Q000601:surgery*; D003362:Cost-Benefit Analysis; D006801:Humans; D008991:Monitoring, Physiologic / Q000191:economics; D009364:Neoplasm Recurrence, Local; D011182:Postoperative Care / Q000191:economics*; D012004:Rectal Neoplasms / Q000191:economics / Q000401:mortality / Q000601:surgery*; D015996:Survival Rate